Eli Lilly SG&A Expenses 2010-2024 | LLY

Eli Lilly annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
  • Eli Lilly sg&a expenses for the quarter ending September 30, 2024 were $2.100B, a 16.4% increase year-over-year.
  • Eli Lilly sg&a expenses for the twelve months ending September 30, 2024 were $8.094B, a 13.65% increase year-over-year.
  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
  • Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.
  • Eli Lilly annual sg&a expenses for 2021 were $6.432B, a 5.07% increase from 2020.
Eli Lilly Annual SG&A Expenses
(Millions of US $)
2023 $7,403
2022 $6,440
2021 $6,432
2020 $6,121
2019 $6,214
2018 $5,975
2017 $5,982
2016 $6,528
2015 $6,533
2014 $6,621
2013 $7,126
2012 $7,514
2011 $7,880
2010 $7,053
2009 $6,893
Eli Lilly Quarterly SG&A Expenses
(Millions of US $)
2024-09-30 $2,100
2024-06-30 $2,117
2024-03-31 $1,952
2023-12-31 $1,925
2023-09-30 $1,804
2023-06-30 $1,925
2023-03-31 $1,749
2022-12-31 $1,643
2022-09-30 $1,614
2022-06-30 $1,625
2022-03-31 $1,558
2021-12-31 $1,592
2021-09-30 $1,578
2021-06-30 $1,686
2021-03-31 $1,576
2020-12-31 $1,554
2020-09-30 $1,569
2020-06-30 $1,449
2020-03-31 $1,550
2019-12-31 $1,698
2019-09-30 $1,412
2019-06-30 $1,586
2019-03-31 $1,517
2018-12-31 $1,694
2018-09-30 $1,457
2018-06-30 $1,486
2018-03-31 $1,339
2017-12-31 $1,106
2017-09-30 $1,579
2017-06-30 $1,730
2017-03-31 $1,568
2016-12-31 $1,866
2016-09-30 $1,565
2016-06-30 $1,623
2016-03-31 $1,474
2015-12-31 $1,798
2015-09-30 $1,576
2015-06-30 $1,635
2015-03-31 $1,524
2014-12-31 $1,800
2014-09-30 $1,672
2014-06-30 $1,664
2014-03-31 $1,485
2013-12-31 $1,954
2013-09-30 $1,652
2013-06-30 $1,868
2013-03-31 $1,652
2012-12-31 $1,978
2012-09-30 $1,757
2012-06-30 $1,931
2012-03-31 $1,848
2011-12-31 $2,133
2011-09-30 $1,918
2011-06-30 $2,043
2011-03-31 $1,786
2010-12-31 $1,989
2010-09-30 $1,695
2010-06-30 $1,755
2010-03-31 $1,614
2009-12-31 $1,953
2009-09-30 $1,702
2009-06-30 $1,708
2009-03-31 $1,529
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $692.744B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94